Profile data is unavailable for this security.
About the company
Getinge AB is a Sweden-based company operating within healthcare sector. The Company provides hospitals and Life Science institutions with products and solutions aimed at improving clinical outcomes and optimizing workflows. The Company’s reporting segments have the following activities: Acute Care Therapies develops solutions for life-sustaining care in acute health conditions. Life Science offers a comprehensive range of equipment, technical expertise and prevention consultation contamination in pharmaceutical production, biomedical research, production of medical equipment and in various laboratory applications. Surgical Workflows offers products and services for the effective disinfection and sterilization of instruments used in operations, operating tables and others hardware for operating rooms and advanced IT systems for efficient and secure workflows in hospitals.
- Revenue in SEK (TTM)32.20bn
- Net income in SEK2.28bn
- Incorporated1990
- Employees11.86k
- LocationGetinge ABLindholmspiren 7,P.O. Box 8861GOETEBORG 417 56SwedenSWE
- Phone+46 35155500
- Fax+46 8295532
- Websitehttps://www.getinge.com/
More ▼
Mergers & acquisitions
| Acquired company | GETI B:STO since announced | Transaction value |
|---|---|---|
| Healthmark Industries Co Inc | 14.83% | 320.00m |
| High Purity New England Inc | -6.77% | 289.66m |
Data delayed at least 15 minutes, as of May 07 2024 17:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xvivo Perfusion AB | 642.95m | 100.43m | 11.92bn | 148.00 | 114.11 | 5.95 | 72.32 | 18.54 | 3.32 | 3.32 | 21.18 | 63.59 | 0.322 | 1.28 | 4.27 | 4,018,431.00 | 5.03 | 1.24 | 5.49 | 1.33 | 73.94 | 73.14 | 15.62 | 4.76 | 3.40 | -- | 0.0152 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
| Biotage AB | 1.98bn | 236.00m | 13.55bn | 669.00 | 56.23 | 3.48 | 33.61 | 6.84 | 3.01 | 3.01 | 25.57 | 48.61 | 0.5276 | 2.01 | 7.78 | 2,939,169.00 | 6.29 | 10.74 | 7.33 | 12.77 | 62.19 | 61.34 | 11.91 | 15.77 | 1.52 | 8.95 | 0.062 | 40.11 | 18.90 | 15.37 | -8.21 | 7.97 | 14.05 | 1.30 |
| Embla Medical hf | 8.70bn | 615.75m | 19.83bn | 4.00k | 32.12 | 2.50 | 16.95 | 2.28 | 0.9243 | 0.9243 | 13.04 | 11.86 | 0.5582 | 2.20 | 6.60 | 1,392,992.00 | 3.96 | 4.06 | 4.68 | 4.76 | 61.41 | 62.47 | 7.09 | 6.91 | 1.07 | 5.81 | 0.4325 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
| Elekta AB (publ) | 18.22bn | 1.43bn | 29.19bn | 4.58k | 21.16 | 2.95 | 11.52 | 1.60 | 3.74 | 3.74 | 47.60 | 26.82 | 0.6208 | 3.29 | 2.90 | 4,150,570.00 | 4.89 | 4.32 | 8.69 | 7.89 | 37.90 | 39.93 | 7.88 | 7.68 | 0.8219 | 4.02 | 0.4106 | 65.79 | 15.95 | 7.83 | -18.28 | -6.90 | 12.86 | 11.38 |
| Ambu A/S | 7.65bn | 371.68m | 42.82bn | 4.70k | 129.47 | 5.73 | 46.16 | 5.60 | 0.9014 | 0.9014 | 18.71 | 20.36 | 0.7075 | 2.00 | 7.26 | 1,060,875.00 | 3.44 | 3.81 | 3.97 | 4.62 | 56.97 | 59.37 | 4.86 | 5.43 | 1.30 | 7.20 | 0.1038 | 22.89 | 7.45 | 12.88 | 80.65 | -13.00 | 6.67 | -- |
| GN Store Nord A/S | 28.44bn | 837.07m | 49.12bn | 7.05k | 56.36 | 3.05 | 13.86 | 1.73 | 3.70 | 3.70 | 127.04 | 68.44 | 0.6139 | 3.00 | 4.73 | 2,541,382.00 | 1.94 | 4.91 | 3.22 | 7.44 | 50.50 | 53.29 | 3.16 | 6.82 | 0.4118 | 2.50 | 0.5582 | 36.84 | -3.03 | 11.30 | -55.38 | -28.74 | 7.53 | -- |
| Getinge AB | 32.20bn | 2.28bn | 59.09bn | 11.86k | 27.73 | 1.96 | 14.93 | 1.84 | 8.39 | 8.39 | 118.22 | 118.80 | 0.6001 | 2.53 | 6.79 | 2,742,908.00 | 4.29 | 5.31 | 5.56 | 6.98 | 45.37 | 47.83 | 7.15 | 8.69 | 0.7569 | 11.47 | 0.2035 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
| Demant A/S | 35.05bn | 3.99bn | 108.07bn | 21.62k | 27.37 | 7.46 | -- | 3.08 | 11.44 | 8.05 | 100.58 | 41.97 | 0.7431 | 2.05 | 5.88 | 1,037,923.00 | 8.46 | 8.27 | 12.20 | 13.23 | 73.72 | 74.14 | 11.38 | 11.34 | 0.9529 | 5.98 | 0.6075 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
| Coloplast A/S | 39.04bn | 7.60bn | 286.45bn | 15.75k | 38.88 | 12.97 | 30.65 | 7.34 | 22.44 | 22.44 | 115.20 | 67.27 | 0.5794 | 2.40 | 5.99 | 1,593,232.00 | 11.28 | 20.45 | 17.11 | 29.69 | 66.74 | 67.91 | 19.47 | 21.73 | 0.3462 | 11.08 | 0.5885 | 91.08 | 8.51 | 8.29 | 1.64 | 4.46 | 13.15 | 5.59 |
Data as of May 07 2024. Currency figures normalised to Getinge AB's reporting currency: Swedish Krona SEK
36.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 Jul 2023 | 20.86m | 8.21% |
| AMF Fonder ABas of 29 Aug 2023 | 13.56m | 5.34% |
| Swedbank Robur Fonder ABas of 13 Mar 2024 | 13.53m | 5.32% |
| The Vanguard Group, Inc.as of 31 Jul 2023 | 8.13m | 3.20% |
| Didner & Gerge Fonder ABas of 31 Jul 2023 | 7.54m | 2.97% |
| Incentive ASas of 31 Jul 2023 | 7.34m | 2.89% |
| Handelsbanken Fonder ABas of 31 Jul 2023 | 6.52m | 2.56% |
| Norges Bank Investment Managementas of 31 Jul 2023 | 5.52m | 2.17% |
| Carnegie Fonder ABas of 31 Jul 2023 | 5.50m | 2.17% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 3.65m | 1.44% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
